J Infect Dis by Shah, N Sarita et al.
Getting to Zero New Tuberculosis Infections: Insights From the 
National Institutes of Health/US Centers for Disease Control and 
Prevention/Bill & Melinda Gates Foundation Workshop on 
Research Needs for Halting Tuberculosis Transmission
N. Sarita Shah1, Peter Kim2, Bavesh Davandra Kana4,5, and Roxana Rustomjee3
1Division of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, 
Atlanta, Georgia 2Office of AIDS Research, National Institutes of Health, Rockville, Maryland 
3Tuberculosis Clinical Research Branch, Division of AIDS, National Institutes of Health, Rockville, 
Maryland 4Department of Science and Technology-National Research Foundation (DST-NRF) 
Centre of Excellence for Biomedical TB Research, Faculty of Health Sciences, University of the 
Witwatersrand, National Health Laboratory Service, Johannesburg 5Medical Research Center-
Center for the AIDS Programme of Research in South Africa (MRC-CAPRISA) HIV-TB 
Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in 
South Africa, CAPRISA, Durban, South Africa
Tuberculosis caused an estimated 1.4 million deaths in 2015 and now ranks as the leading 
infectious disease cause of mortality in the world [1]. An additional 1.7 billion people are 
currently infected with Mycobacterium tuberculosis and are at risk of developing active 
tuberculosis disease. The challenge to eliminate tuberculosis has never been more relevant 
and urgent. Unfortunately, efforts to bring this global epidemic under control have been 
hampered by inadequate understanding of the epidemiology, biology, and effective 
interventions that directly address tuberculosis transmission. Identifying the key drivers of 
transmission and appending interventions has thus far remained unattainable in many high-
burden tuberculosis settings. The large reservoir of subclinical infections, the human 
immunodeficiency virus (HIV) coepidemic, and a rise in drug resistance make public health 
efforts to battle this disease complex. For example, in southern Africa, high rates of HIV 
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infection have served as key drivers of the tuberculosis epidemic and have created a complex 
clinical situation with unique difficulties in diagnosis and tracking infectious individuals; 
these limitations have seriously hampered tuberculosis elimination in the region [1]. In the 
United States, intermittent outbreaks of tuberculosis continue to occur despite utilization of 
modern prevention interventions in a well-funded healthcare system [2]. Globally, the 
modest declines (of 1.5%) in tuberculosis incidence between 2014 and 2015 fall markedly 
short of the targeted 4%–5% annual decline that is needed to achieve the 2020 milestones for 
the global End TB Strategy [3]. Of particular concern, the massive rollouts of new 
interventions targeted at individual patients, such as molecular diagnostics, preventative 
therapy, and antiretroviral treatment, and infrastructure investments in renovating healthcare 
facilities to reduce airborne disease spread have not resulted in sufficient epidemiological 
impact to meet global goals in reducing tuberculosis incidence [4, 5]. This highlights the 
need for sharply focused, evidence-led interventions and strategies tailored to individuals 
and communities, which are complemented by an ambitious implementation science agenda 
that rapidly translates new research findings to the field. Central to this process should be a 
paradigm shift toward limiting transmission with improved efficiency and effectiveness and 
the incorporation of strategies for overcoming the stigma and discrimination that continues 
to dilute the uptake and utilization of health services.
The issue of transmission is at the core of nearly every infectious disease epidemic and 
begins with understanding among whom, where, and how a disease is being spread and how 
this spread is amplified by risk factors and drivers at an individual and community level. 
Conventionally, we know tuberculosis is spread from person to person through airborne 
transmission of tubercle bacteria via droplet nuclei expelled by an infectious person in close 
proximity of a susceptible individual. Sufficient sharing of air space is important for a 
successful chain of transmission. Only a small proportion of individuals infected with M. 
tuberculosis develop active TB disease; the large majority are able to contain or eliminate 
infection. Individuals with compromised immunity (eg, HIV, diabetes, older age, 
malnutrition) or underlying lung disease are at high risk of developing active tuberculosis 
disease. The development of active tuberculosis, which results in lung damage and 
respiratory insufficiency, creates the opportunity for transmission of infection to other 
susceptible individuals. A critical factor driving tuberculosis transmission is the availability 
of a large pool of individuals who can be infected; vaccination provides a marginal benefit to 
the adolescent and adult population. Furthermore, individuals who previously had 
tuberculosis infection or tuberculosis disease and have been cured can become reinfected, 
particularly in high-burden settings where they are repeatedly re-exposed to bacteria.
In March 2016, the National Institutes of Health (NIH), US Centers for Disease Control and 
Prevention (CDC), and the Bill & Melinda Gates Foundation convened a 2-day meeting of 
physicians, research scientists, individuals working in public health, and other stakeholders 
to discuss the current state of the art regarding tuberculosis transmission and what is needed 
to truly transform our approach to halting new infections. Moving beyond implementing 
existing tools—which have the potential to create impact in focused, strong programs—to 
the point of having game-changers that will redirect effort and resources was the main 
objective of the dialogue. The workshop took a holistic approach to transmission and served 
as a platform to catalyze ideas and crystallize a vision for elimination of tuberculosis by 
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highlighting transmission-blocking strategies as the central component of the overall effort 
directed at this deadly disease.
The articles in this supplement present the 3 major thematic areas addressed in the 
workshop. First, who is infectious and who gets infected? Second, what are the factors that 
drive transmission in the community? Third, how should interventions be designed and 
evaluated for maximal impact? The supplement closes with a research roadmap that outlines 
priority areas for tuberculosis transmission science and some metrics for measuring progress 
toward those goals. Together, these articles provide a comprehensive review of the current 
state of tuberculosis transmission science and a vision for the way forward to inform future 
research. The presentations from the workshop are publically available at http://
tbtw.auruminstitute.org/. A follow-up workshop was held in June 2017 in Cape Town, South 
Africa; it focused specifically on halting tuberculosis transmission in HIV-endemic settings, 
where the risk of tuberculosis infection and consequences of tuberculosis disease are most 
dire.
It is a profoundly sad reality that modern medicine is defined by the fact that a person dies of 
tuberculosis every 20 seconds. No longer can we ignore the growing menace of tuberculosis 
and the heartfelt plight of those suffering with this disease. We anticipate that this 
supplement will be an urgent call to action to address tuberculosis transmission with 
renewed vigor using a focused, multidimensional strategy that calls on the strengths of all 
disciplines. With this unified approach, we will see an end to tuberculosis.
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